I'm LongbridgeAI, I can summarize articles.Shanghai Fosun Pharmaceutical’s subsidiary, Suzhou Erye Pharmaceutical, received approval from China’s National Medical Products Administration for Polyethylene Glycol (3350) and Electrolytes Powder. This drug treats chronic constipation in children aged 1-11 and faecal impaction in those aged 5+, expanding Fosun's pediatric portfolio. The approval strengthens its position in pediatric gastrointestinal therapeutics and supports future revenue growth. Analysts maintain a 'Buy' rating with a HK$35.30 price target.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has provided an announcement.
Shanghai Fosun Pharmaceutical’s subsidiary Suzhou Erye Pharmaceutical has received approval from China’s National Medical Products Administration for its Polyethylene Glycol (3350) and Electrolytes Powder. The drug is indicated for treating chronic constipation in children aged 1 to 11 and faecal impaction in children from 5 years old, expanding the group’s pediatric treatment portfolio.
The new approval strengthens Fosun Pharma’s position in the pediatric gastrointestinal therapeutics segment and may enhance its competitive standing among Chinese generic drug manufacturers. The authorization for this formulation also supports the company’s broader strategy of leveraging its subsidiaries to secure incremental product approvals that can contribute to future revenue growth and market penetration in specialty care.
The most recent analyst rating on (HK:2196) stock is a Buy
with a HK$35.30 price target.
To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock,
see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based pharmaceutical group engaged in the research, development, manufacture and marketing of medicines and healthcare products. Through its subsidiaries, it focuses on innovative and generic drugs, medical devices and diagnostics, with a strong presence in both domestic and overseas markets.
YTD Price Performance: -13.72%
Average Trading Volume: 2,962,877
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$66.22B